Business Wire
BusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex Times
Back to front
Ahead of Its Next Earnings Report, Salesforce (CRM) Faces a Steep Setup, Yahoo Finance Says
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 11:26 AM EDT

Ahead of Its Next Earnings Report, Salesforce (CRM) Faces a Steep Setup, Yahoo Finance Says

A Yahoo Finance market piece argues Salesforce may not have the right ingredients for an earnings beat, even as investors watch for signs of continued momentum.

3 min readEditor-approved Apex article

Salesforce (NYSE:CRM) is heading into its next earnings report with investors searching for confirmation that demand for its customer-relationship management software remains durable. In a market-focused preview published Tuesday, Yahoo Finance framed the setup as less favorable than bulls would prefer, saying the company does not currently have the “right combination of the two key ingredients” that would make a beat more likely.

The Yahoo Finance article does not, in its title framing alone, specify which two ingredients it is referring to, nor does it provide the underlying forecasts, analyst expectations, or valuation indicates in the information available here. What the piece does make clear is that it is counseling readers to “get prepared with the key expectations,” implying that the market will be looking closely at near-term results rather than only longer-term strategy.

Salesforce’s earnings are closely tied to how subscriptions and enterprise software spending evolve as customers weigh priorities across customer service, sales automation, marketing, and data-related capabilities. For shareholders, the question ahead of any quarter is typically whether the company can show steady commercial traction, maintain healthy retention, and pair that with progress in higher-value offerings such as artificial intelligence features and platform expansion, all while costs and guidance stay credible.

In its market-news framing, the Yahoo Finance preview suggests that Salesforce’s balance of strengths and weaknesses might not line up in time for a likely upside surprise. That view matters because earnings beats can be driven not only by headline revenue growth, but also by operating leverage, margin discipline, and the ability to raise or confirm guidance. When any of those pieces are missing, the probability of a clean beat can drop even if the business remains fundamentally intact.

Salesforce’s long-running role in the enterprise software market also means the company is often judged against peers with similar cloud and customer engagement portfolios. When broader enterprise IT budgets tighten or when companies delay discretionary technology projects, software vendors can see quarter-to-quarter volatility, especially around deal cycles, upgrades, and new deployments.

The company’s latest communications can provide context for what management is emphasizing operationally going into a results window, including product direction, AI initiatives, and enterprise customer announcements. Salesforce maintains a newsroom with updates, which investors typically scan for indicates that new product capacity, AI adoption, or customer wins are translating into commercial outcomes. However, the Yahoo Finance preview itself, based on what is available here, does not substitute for those disclosures and stays focused on the earnings setup rather than specific product milestones.

One important caveat is that the available material here includes only the Yahoo Finance headline and description, not the full text of the article. As a result, key details that would normally be essential to evaluate the claim, such as the specific “two key ingredients,” the expected earnings range, guidance outlook, and which metrics the author believes are likely to miss, cannot be confirmed from the information provided for this editorial draft. Readers should treat the “should you buy” framing as a commentary on probabilities, not as a comprehensive forecast.

What to watch next is straightforward once Salesforce reports: whether it delivers on the market’s expectations for revenue growth and profitability, whether management’s guidance matches or changes the trajectory implied by prior quarters, and whether any AI-related or platform expansion themes show up in measurable demand indicators. Those items will determine whether the skepticism implied by the Yahoo Finance preview holds up or is overtaken by stronger-than-feared results.

Why It Matters

  • Earnings previews that argue against a likely beat can influence positioning into the report, especially for investors sensitive to near-term results rather than longer-term narratives.
  • If the company’s eventual guidance or profitability profile comes in below what markets expect, it can affect stock moves regardless of longer-term product strategy.
  • Conversely, even without a beat, Salesforce could still be viewed as stable if results align with expectations and management guidance reduces uncertainty.
  • The next report will clarify whether the factors behind the Yahoo Finance skepticism are confirmed by reported metrics or are outweighed by stronger operational execution.

Sources

Key Facts

  • Salesforce trades on the New York Stock Exchange under the ticker CRM.
  • On 2026-08-19, Yahoo Finance published a market-news preview titled around whether Salesforce earnings are expected to grow and whether that implies a “buy” setup.
  • The Yahoo Finance preview characterizes Salesforce as not having the “right combination of the two key ingredients” for a likely earnings beat.
  • The preview directs readers to prepare for specific “key expectations,” indicating that near-term results and metrics will be closely scrutinized when Salesforce reports.
  • Salesforce maintains an official newsroom that investors may consult for product and AI updates around the earnings period.

Technology Related